20th April 2016, SomnoMed Limited
(ASX:SOM) announced that continuing high growth in its volume of sales of its sleep apnea devices resulted in it recording a growth of 28% of its sleep apnea device sales revenues to $9.2m (unaudited). Total group revenues, which include non-device managed care revenues and sale of various supplementary products, amounted to $11.1m (unaudited), up by 32% compared to the third quarter in the previous year.
High revenue growth was driven by the growth in sales of SomnoDent® devices in all global regions and was further fuelled by growing managed care revenues in the US and Europe.
For further information please download PDF attached:
